Mylan says it expects supply of its biosimilar insulin glargine (SEMGLEE) by the end of October as Sanofi fills the gap with a new brand of the originator.
Latest Video
New Stories
-
Mayne Pharma bets on an untapped corner of the menopause market
September 17, 2026 - - Latest News -
Genomic testing to reach more patients with hard to treat cancers
September 17, 2026 - - Latest News -
Eight women named finalists for 2026 Marie Krogh Young Women in Science Prize
September 17, 2026 - - Latest News -
'Your success makes you a target and take it as a compliment'
September 16, 2026 - - Latest News -
New research points to a 'Doctor gap' holding back clinical trial participation in Australia
September 16, 2026 - - Latest News -
New Zealand ranks last among wealthy nations on modern medicines access, new report finds
September 16, 2026 - - Latest News -
Young Australians badly misjudge when fertility starts to decline, new survey finds
September 16, 2026 - - Latest News
